Last updated: August 5, 2026
Buprenorphine/naloxone is a mature opioid-use-disorder market with continuing commercial potential in sublingual films, tablets, buccal systems, long-acting formulations, and abuse-deterrent delivery technologies. The highest-value excipient opportunities are in rapid wetting, taste masking, mucoadhesion, dose uniformity, moisture control, film integrity, and lower-cost manufacturing.
The leading commercial products are Indivior's SUBOXONE sublingual film, Orexo's ZUBSOLV sublingual tablet, and generic buprenorphine/naloxone tablets and films. The combination is usually supplied at a 4:1 buprenorphine-to-naloxone ratio, including 2 mg/0.5 mg and 8 mg/2 mg strengths. Buprenorphine provides opioid agonist activity with a ceiling effect on respiratory depression. Naloxone is included to reduce the attractiveness of injection or other parenteral misuse because it has limited sublingual bioavailability but can precipitate withdrawal when injected by an opioid-dependent person [1,2].
What products contain buprenorphine and naloxone?
The FDA-approved combination is available primarily as sublingual tablets and sublingual films. Product availability varies by manufacturer, dosage strength, state procurement channel, and pharmacy contracts.
| Product |
Sponsor or manufacturer |
Dosage form |
FDA approval status |
Primary excipient opportunity |
| SUBOXONE |
Indivior |
Sublingual film |
Approved under NDA 022410 |
Film mechanics, taste masking, moisture barrier, rapid dissolution |
| ZUBSOLV |
Orexo |
Sublingual tablet |
Approved under NDA 204242 |
Porosity, tablet disintegration, flavor, low-dose content uniformity |
| Generic products |
Multiple ANDA sponsors |
Sublingual tablets and films |
FDA-approved products exist |
Cost reduction, bioequivalence, manufacturing robustness |
| BUNAVAIL |
BioDelivery Sciences |
Buccal film |
FDA-approved; commercial status has changed over time |
Buccal adhesion, residence time, dose transfer |
| Sublocade |
Indivior |
Monthly injectable buprenorphine |
Buprenorphine-only product |
Not a direct naloxone combination opportunity |
SUBOXONE film uses a polymeric oral film designed to adhere to the sublingual mucosa and dissolve without water. Its inactive ingredients include film-forming polymers, plasticizing or structural components, sweeteners, flavoring agents, buffering agents, and colorants. ZUBSOLV uses a rapidly disintegrating sublingual tablet with a different excipient architecture and a lower tablet mass than conventional oral tablets [3,4].
Which excipients are used in buprenorphine/naloxone products?
Excipient selection is driven by the sublingual route, low drug loading, bitter taste, rapid onset, and the need to maintain a small dosage unit.
Film-forming excipients
Sublingual films generally require a water-soluble polymer matrix that can:
- Form a continuous film at low thickness.
- Release both active ingredients rapidly.
- Resist cracking during packaging and handling.
- Adhere to wet mucosa.
- Maintain dose uniformity across the web.
- Limit drug migration during drying and storage.
SUBOXONE labeling identifies polyethylene oxide and hydroxypropyl methylcellulose among its inactive ingredients. Maltodextrin, citric acid, sodium citrate, acesulfame potassium, flavoring, and colorant are also listed for the product [3].
Potential commercial excipient platforms include hydroxypropyl cellulose, hydroxypropyl methylcellulose, pullulan, maltodextrin, polyethylene oxide, polyvinyl alcohol, and selected starch derivatives. The preferred polymer is not necessarily the one with the fastest dissolution. Excessive hydration can cause tackiness, poor die-cutting, and packaging adhesion.
Tablet disintegrants and pore-forming systems
Sublingual tablets need to break apart quickly after contact with saliva. Useful formulation tools include:
- Mannitol for mouthfeel and water-soluble bulk.
- Microcrystalline cellulose for compression and mechanical strength.
- Crospovidone or related disintegrants for rapid breakup.
- Colloidal silicon dioxide for flow and moisture management.
- Citric acid or citrate systems for local pH control.
- Low levels of lubricants to avoid slowing wetting.
ZUBSOLV uses a compact, fast-disintegrating tablet platform. Its listed inactive ingredients include mannitol, microcrystalline cellulose, citric acid, colloidal silicon dioxide, sucralose, magnesium stearate, acesulfame potassium, and flavoring agents [4].
The principal technical challenge is balancing hardness and disintegration. A tablet that is too soft creates friability and packaging losses. A tablet that is too hard can delay sublingual release and produce inconsistent exposure.
Taste-masking excipients
Buprenorphine and naloxone can create a strong bitter or medicinal taste. Taste masking is important because the treatment is administered repeatedly, often daily, and poor palatability can impair persistence.
Commercial approaches include:
- High-intensity sweeteners such as acesulfame potassium or sucralose.
- Flavor systems selected for rapid release rather than prolonged oral retention.
- pH adjustment to reduce perceived bitterness.
- Ion-exchange resins or polymeric complexes.
- Lipid or polymer microencapsulation.
- Reduced exposure of undissolved particles in the mouth.
- Fast dissolution that minimizes residual taste.
Taste masking must not create a slow-release coating that changes the buprenorphine or naloxone absorption profile. For an ANDA product, any taste-masking system that materially changes formulation behavior may increase bioequivalence and regulatory complexity.
Mucoadhesive excipients
Mucoadhesion is more important for buccal products than for conventional sublingual tablets. Candidates include polycarbophil, carbomers, polyvinylpyrrolidone, cellulose derivatives, xanthan gum, and selected thiolated polymers.
A strong mucoadhesive can increase residence time and reduce swallowed drug. Excessive adhesion can create poor patient acceptability, local irritation, or slow drug release. A commercial formulation should target reliable placement and dissolution rather than maximum adhesion.
Buffering and pH-control systems
Local pH affects buprenorphine ionization, dissolution, mucosal permeation, and taste. Citric acid and sodium citrate are used in approved products. Other buffer systems may be technically attractive but can increase irritation, alter saliva response, or change the ratio of dissolved and undissolved drug.
A practical excipient program should evaluate:
- Dissolution in simulated saliva.
- Sublingual permeation.
- Salivary pH after dosing.
- Drug precipitation after wetting.
- Stability under high humidity.
- Taste over the full dissolution period.
What excipient strategies have the strongest commercial potential?
The strongest opportunities are not simple substitutions of one filler or sweetener. They are integrated excipient systems that improve a measurable product attribute.
1. Lower-cost sublingual films
A generic or authorized-generic film can compete through lower polymer cost, higher coating-line yield, reduced drying time, and fewer packaging defects. The commercial value is significant because film manufacturing can be more sensitive to viscosity, web handling, humidity, and die-cutting than tablet compression.
A differentiated film platform could target:
- Lower total film mass.
- Faster drying.
- Reduced residual solvent or water.
- Improved roll-to-roll yield.
- Better dose uniformity at low strengths.
- Improved resistance to curling and edge cracking.
- Less expensive unit-dose packaging.
2. Improved taste and mouthfeel
Palatability is a practical adherence variable in chronic opioid-use-disorder treatment. A formulation that reduces bitterness without prolonging residence time could support payer, prescriber, and patient switching.
The most defensible product concept would combine a sweetener-flavor system with fast dissolution and limited residual particulate matter. A taste-masking patent based only on a conventional sweetener is likely to be weak unless it produces an unexpected stability, dissolution, or adherence result.
3. Moisture-resistant packaging and excipient systems
Sublingual films and rapidly disintegrating tablets are vulnerable to humidity. Moisture can change tensile strength, sticking, disintegration, dissolution, and assay uniformity.
Commercial opportunities include:
- High-barrier individual sachets.
- Desiccant-integrated packaging.
- Moisture-scavenging secondary packaging.
- Polymer blends with lower hygroscopicity.
- In-line humidity controls.
- Stability-indicating specifications linked to mechanical performance.
Packaging is often as important as the excipient itself. A formulation that performs well only in expensive foil packaging may lose its cost advantage.
4. Pediatric-resistant and misuse-resistant presentations
The FDA has approved buprenorphine/naloxone for opioid-use-disorder treatment in adults and, under labeling changes, certain adolescents. Pediatric exposure remains a major safety concern. Small, individually sealed units, strong child-resistant packaging, and reduced residual drug transfer can create commercial differentiation [5].
Potential product claims include:
- Reduced accidental exposure from handling.
- Reduced transfer from partially dissolved films.
- Unit-dose control.
- Improved counting and dispensing.
- Better storage stability outside controlled clinic settings.
Claims directed to abuse deterrence require careful validation. Changing taste or dissolution alone does not establish resistance to misuse.
What patents protect buprenorphine/naloxone formulations?
The key patent categories are formulation patents, oral-film manufacturing patents, dosage-form patents, and method-of-use patents. The most commercially relevant estate has historically been associated with Indivior's SUBOXONE film platform and Orexo's ZUBSOLV tablet technology.
| Patent category |
Typical protected subject matter |
Commercial relevance |
| Sublingual film composition |
Polymer matrix, active distribution, film thickness, excipient ratios |
Can delay or complicate generic film entry |
| Film manufacturing |
Solvent casting, drying, cutting, web handling, uniformity |
Creates manufacturing barriers even where composition claims are narrow |
| Sublingual tablet |
Porosity, compression profile, excipient combinations, disintegration |
Relevant to ZUBSOLV and generic tablet competition |
| Taste masking |
Sweeteners, flavors, encapsulation, pH systems |
Usually strongest when linked to performance data |
| Buccal delivery |
Mucoadhesion, multilayer films, residence time |
Relevant to BUNAVAIL-type products |
| Method of use |
Opioid-use-disorder treatment, dosing, induction, maintenance |
May restrict specific labeled-use strategies |
| Packaging |
Moisture barrier, unit-dose presentation, child resistance |
Supports lifecycle management but is easier to design around |
The FDA Orange Book, patent certifications, and court dockets must be reviewed product by product because listed patents, pediatric extensions, terminal disclaimers, and litigation outcomes can alter the practical expiry date [6].
When does buprenorphine/naloxone lose exclusivity?
The combination no longer has broad market exclusivity in the way a newly approved drug would. Generic sublingual tablets have been available for years, and generic film competition has also entered the market.
The relevant exclusivity questions are now narrower:
- Is the target product a tablet or film?
- Is the ANDA applicant seeking the same dosage form?
- Are Orange Book-listed patents still enforceable?
- Does the generic rely on Paragraph III or Paragraph IV certifications?
- Is the product strength covered by the same patent claims?
- Does the applicant challenge formulation or manufacturing patents?
- Are there non-patent barriers involving bioequivalence, film uniformity, or device-like packaging?
For most commercial planning, the product-specific generic entry date is more important than the original NDA exclusivity date. A Paragraph IV challenge can trigger litigation and a potential 30-month stay under the Hatch-Waxman framework, but the actual launch outcome depends on patent scope, court rulings, settlements, and regulatory approval [7].
Which companies are challenging or competing with branded products?
Competition comes from several groups:
Generic manufacturers
Generic manufacturers compete on price, pharmacy substitution, wholesaler access, and reliable supply. Tablet products generally have lower manufacturing complexity than films. Film manufacturers can compete where patient preference, prescriber continuity, or payer coverage supports the dosage form.
Indivior
Indivior has historically protected SUBOXONE film through formulation, manufacturing, and product lifecycle patents. The company also shifted commercial emphasis toward long-acting buprenorphine products, including SUBLOCADE, which competes for the same opioid-use-disorder treatment population but does not contain naloxone.
Orexo
Orexo's ZUBSOLV uses a proprietary sublingual tablet platform and has competed through tablet size, rapid disintegration, flavor, and product handling. Its formulation technology is relevant to companies seeking a compact tablet with improved patient acceptability.
Long-acting buprenorphine manufacturers
SUBLOCADE and BRIXADI use injectable buprenorphine depots rather than buprenorphine/naloxone. These products compete for adherence-sensitive patients and reduce daily dosing. They do not directly replace the naloxone combination for every patient, particularly where clinicians prefer the established sublingual induction and maintenance pathway [8,9].
What FDA regulatory issues affect new excipient strategies?
A new buprenorphine/naloxone product generally follows one of three regulatory routes:
| Route |
Typical use |
Main regulatory issue |
| ANDA |
Same active ingredients, strength, dosage form, and route as a reference product |
Pharmaceutical equivalence and bioequivalence |
| 505(b)(2) NDA |
Modified formulation, new delivery system, or other reliance on existing data |
Clinical bridging, formulation differences, and patent certifications |
| Full NDA |
Novel combination or materially new delivery technology |
Full safety and efficacy program |
For a sublingual film, FDA review is likely to focus on content uniformity, film dimensions, mechanical properties, residual solvents, dissolution, drug release, impurities, stability, and in vitro or clinical bioequivalence. For tablets, disintegration, dissolution, hardness, friability, blend uniformity, and dose uniformity are central.
Excipients with established oral use have a lower regulatory burden than novel mucosal permeation enhancers, new bioadhesive polymers, or excipients used at materially higher exposure levels. A formulation that changes buprenorphine absorption may require more than a routine generic development package.
How strong is the patent estate for buprenorphine/naloxone?
The estate is strongest where formulation claims are tied to a specific delivery architecture and measurable performance result. Examples include:
- Defined polymer ratios that produce a stable film.
- Drug distribution across a continuous film web.
- Specific drying or casting parameters.
- Multilayer structures that separate incompatible components.
- Tablet porosity and disintegration combinations.
- Mucoadhesive systems with defined residence and release behavior.
The estate is weaker where claims cover conventional excipients at broad concentrations without a clear technical effect. A new excipient strategy should generate patentable data around:
- Faster dissolution at equivalent exposure.
- Improved humidity stability.
- Reduced bitterness.
- Lower film defect rates.
- Reduced drug migration during drying.
- Improved dose uniformity.
- Lower packaging requirements.
- Reduced accidental transfer or pediatric exposure.
Freedom-to-operate analysis must cover composition, process, dosage form, packaging, labeling, and method-of-use claims in the United States, Europe, Canada, Australia, and other target markets.
What generic launch scenarios exist?
Low-cost sublingual tablet
This is the lowest technical-risk opportunity. The product can target state Medicaid formularies, retail pharmacies, correctional health systems, and opioid-treatment programs. Margin pressure is high, so manufacturing yield and procurement scale are critical.
Differentiated sublingual film
A film with superior taste, lower moisture sensitivity, faster dissolution, or more convenient packaging can compete despite generic tablet availability. The product requires stronger formulation and manufacturing control.
Buccal film
A buccal product can target patients who have difficulty placing a sublingual film or who need longer mucosal residence. The regulatory burden rises if the product changes absorption or offers a materially different dosing experience.
505(b)(2) enhanced product
A modified product could combine buprenorphine/naloxone with a new mucoadhesive, abuse-deterrent architecture, or controlled-release feature. The opportunity is commercially larger, but development costs and patent exposure are also higher.
Long-acting combination product
A depot containing both buprenorphine and naloxone could create a differentiated product category, but formulation compatibility, release control, local tolerability, and clinical development would be substantial barriers. Existing long-acting commercial competition currently centers on buprenorphine-only products.
What commercial opportunities exist by geography?
The United States offers the largest opportunity for branded-generic and specialty-formulation development because of the scale of opioid-use-disorder treatment, FDA-approved generic pathways, and established reimbursement channels.
Europe has a more fragmented market and country-specific reimbursement. Sublingual tablets are established, while film opportunities depend on local prescribing and tender systems.
Canada and Australia have established opioid agonist treatment markets but smaller addressable populations. Public procurement, national formularies, and supply reliability can matter more than premium formulation features.
Emerging markets may favor stable, low-cost tablets. In those markets, the strongest value proposition is often manufacturing efficiency, dose consistency, packaging durability, and reliable supply rather than complex excipient innovation.
Key Takeaways
- The primary commercial dosage forms are sublingual films and rapidly disintegrating tablets.
- The most valuable excipient strategies address taste, moisture, dissolution, film yield, and dose uniformity.
- Generic tablets offer the lowest technical and regulatory risk but face substantial price competition.
- Films offer greater differentiation through patient experience, packaging, and manufacturing performance.
- New mucosal permeation enhancers and controlled-release systems increase 505(b)(2) and clinical-development risk.
- Patent value is concentrated in film composition, manufacturing processes, tablet architecture, and performance-linked excipient combinations.
- FDA Orange Book and Paragraph IV analysis must be performed at the individual reference-product level.
- Long-acting buprenorphine products compete commercially but do not directly replace buprenorphine/naloxone in every treatment setting.
- The strongest new IP will connect excipient selection to measurable technical advantages rather than claim conventional ingredients in isolation.
FAQs
Is buprenorphine/naloxone film commercially better than sublingual tablets?
Films can offer better portability, dose handling, and patient acceptance, while tablets usually provide lower manufacturing cost. Commercial performance depends on payer coverage, substitution rules, product supply, and patient preference.
Can a new sweetener support a buprenorphine/naloxone patent?
A sweetener alone is usually a weak basis for a valuable patent. Patent strength improves when the sweetener is part of a defined system that produces improved bitterness, dissolution, stability, or adherence.
What is the main manufacturing barrier for buprenorphine/naloxone films?
The main barriers are uniform drug distribution, web coating, drying control, film cutting, moisture protection, and packaging yield. These factors can be more difficult to control than conventional tablet compression.
Are buprenorphine/naloxone products biologics subject to biosimilar competition?
No. Buprenorphine/naloxone products are small-molecule drug products. Competition follows generic and NDA pathways rather than the biosimilar pathway.
Can a buprenorphine/naloxone product use a novel mucoadhesive polymer?
Yes, but the regulatory pathway depends on the polymer's prior use, exposure, and effect on drug absorption. A novel or materially different mucosal excipient can increase the need for safety, pharmacokinetic, and clinical bridging data.
References
- U.S. Food and Drug Administration. (2023). Suboxone prescribing information.
- Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder. Treatment Improvement Protocol 63.
- Indivior Inc. (2023). Suboxone sublingual film prescribing information.
- Orexo US, Inc. (2023). Zubsolv prescribing information.
- U.S. Food and Drug Administration. (2021). Buprenorphine treatment of opioid use disorder: Frequently asked questions.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- U.S. Food and Drug Administration. (2023). Hatch-Waxman exclusivity and patent certifications.
- Indivior Inc. (2023). Sublocade prescribing information.
- Braeburn Inc. (2023). Brixadi prescribing information.
